[Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]. 2004

Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
Second Affiliated Hospital, Xinxiang Medical College, Xinxiang 453002, China.

OBJECTIVE To study the effects of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia, and explore the role of the cytokines in the psychopathological basis of the illness. METHODS Fifty-eight patients with first-episode paranoid schizophrenia were treated with either clozapine or risperidone, and before and at the end of the 4th, 8th weeks and 6th months after the medication respectively, the serum levels of interleukin (IL)-6, 2, 18,and tumor necrosis factor (TNF)alpha were measured with enzyme-linked immunosorbent assay (ELISA). The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the psychotic symptoms. RESULTS In patients treated with risperidone, the levels of serum IL-6 and IL-2 after 4 weeks, TNFalpha after 8 weeks, and IL-18 after 6 months were all significantly lowered in comparison with the pretreatment levels (P<0.01 or 0.05). In clozapine group, the levels of IL-2 after 4 weeks and IL-6 and IL-18 after 6 months were lowered significantly (P<0.01 or 0.05). Before the medication, serum IL-6 level was positively correlated with Positive Syndrome scores (r=0.386, P<0.01), IL-2 with the total score and Positive Syndrome scores (r=0.338, 0.305; P<0.01, 0.05), and TNFalpha with the total score (r=0.283, P<0.05). The changes of IL-2 and IL-6 after 8 weeks was positively correlated with the change of Positive Syndrome scores (r=0.268, 0.375; P<0.05, 0.01). Six months after the medication, the change in IL-6 and TNFalpha levels was positively correlated with the change of total score (r=0.365, 0.362; P<0.05). Before treatment, IL-6 was positively correlated with IL-2 levels (r=0.356, P<0.01), and TNFalpha with IL-18 levels (r=0.291, P<0.05). TNFalpha was positively correlated with IL-6 levels (r=0.332, P<0.01) 8 weeks after the medication. The changes in IL-6 was positively correlated with the those in IL-2 levels 6 months after the medication (r=0.391, P< 0.05). CONCLUSIONS Clozapine and risperidone have similar immunosuppression actions and may affect serum IL-6 levels in patients with paranoid schizophrenia, in the psychopathology of which the cytokines play their roles of various importance.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008297 Male Males
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012563 Schizophrenia, Paranoid A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination. Delusional Disorder,Paranoid Schizophrenia,Delusional Disorders,Disorder, Delusional,Disorders, Delusional,Paranoid Schizophrenias,Schizophrenias, Paranoid
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
May 2017, Neuroscience letters,
Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
July 2007, International clinical psychopharmacology,
Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
January 2010, International journal of psychiatry in clinical practice,
Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
September 2006, Zhonghua yi xue za zhi,
Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
February 2002, The American journal of psychiatry,
Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
January 2015, Journal of medicine and life,
Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
March 2023, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
November 2018, Neuroscience letters,
Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
November 2016, The Indian journal of medical research,
Lu-xian Lü, and Su-qin Guo, and Wei Chen, and Qiang Li, and Jun Cheng, and Jing-hua Guo
January 2012, Neuro endocrinology letters,
Copied contents to your clipboard!